AKEURA

Fact Sheet

NEUROSCIENCE

Alzheimer's Disease Clinical Development

Fast start-up, stable teams, deep therapeutic knowledge, and the flexibility to adapt.

Built for the Toughest Alzheimer's Trials

With the first disease-modifying therapies now approved, Alzheimer's trials are moving earlier, into populations defined by biomarker evidence and a wider range of imaging and diagnostic tools. Sponsors need partners who know PET, MRI, and CSF biomarkers inside out, along with emerging blood-based methods and neurophysiological tools like EEG.

That makes these studies harder to design and run. Early-stage participants are harder to recruit, and with slower disease progression, showing a treatment effect can take longer studies or more sensitive scales and biomarkers that catch subtle changes over time.

AKEURA pairs academic scientific leadership with global execution and integrated real-world evidence, giving Alzheimer's programs the scientific depth and operational consistency they need, from early development to late-stage trials and beyond.

Focused, science-led specialization in Alzheimer's disease:

140+ studies conducted across neuroscience indications

40% of our neurodegenerative trials are in Alzheimer's disease

1,500+	150+	20+
patients	sites	countries

Where Alzheimer's Trials Get Complicated

Our scientific, medical, and operational teams are ready for:

- Recruiting early-stage participants who may not yet seek care
- Cognitive, imaging, and CSF endpoints, now joined by digital cognitive assessments and blood-based biomarkers
- Functional unblinding and placebo response that cloud signal detection
- High screen-failure rates driven by biomarker requirements
- Rater and site variability, plus regional care differences that affect screen failure, recruitment, retention, and procedure acceptance
- Treatment-naïve vs. treatment-experienced stratification as disease-modifying therapies become more widely used

Global Delivery for Complex Clinical Programs

AKEURA is a full-service CRO with dual expertise in clinical and real-world evidence. We pair academic rigor with consistent senior teams and real-world insight to reduce risk and improve trial performance across complex therapeutic areas, decentralized models, and every phase of development.

The Team Behind Your Study

<5%
turnover, so your team stays your team

20+
years average experience across our team

10+
years minimum experience for MMs, PDs, PMs, and LCRAs

85%
of our team have sponsor and CRO backgrounds

Full-Service Capabilities (Phase I–IV)

Flexible support across the full clinical lifecycle:

Design & Strategy

- Study design, protocol development, feasibility
- Scientific consultation and endpoint strategy

Clinical Execution

- Start-up, regulatory, and site activation
- Rater training, certification, and central/firewalled rating
- Global clinical operations and monitoring
- Patient recruitment and retention

Data, Safety & Reporting

- Data management, biostatistics, and medical writing
- Medical monitoring and safety
- Endpoint adjudication and reporting
- RBQM and centralized monitoring
- Endpoint protection strategies, including rater training, scale reliability, and placebo-response mitigation

Real-World Evidence in Neuroscience

One partner across the evidence lifecycle, from trial to real world:

- Real-world data strategy and study design
- Observational studies and neurology registries
- External control arms and long-term outcome tracking
- Support for regulatory, payer, and lifecycle evidence needs

Your medicine's story doesn't end at approval. Neither do we.

We think like sponsors, work with scientific precision, and build every study around participants and strong site partnerships.

Ready to move your Alzheimer's program forward? Contact us at info@akeura.com.